UPDATE: Jefferies Lowers PT on Dynavax Technologies Following Major FDA Setback
June 11, 2013 at 11:23 AM EDT
In a report published Tuesday, Jefferies analyst Thomas Wei reiterated a Buy rating on Dynavax Technologies (NASDAQ: DVAX ), but lowered the price target from $5.00 to $3.00. In the report, Jefferies noted, “We had previously assumed that DVAX would be able to argue for an expedited pathway to Heplisav approval
